
Product Datasheet





Mouse Anti-Human Fibromodulin

Overview

Product number PDZMM121

Host species Mouse

Target species Human

Suitable for: IHC-P, WB, ELISA, Immunomicroscopy,

Dot blot, ICC, IHC-Fr

Immunogen A KLH-conjugated synthetic peptide derived from human Fibromodulin protein

was used for immunization.

Conjugation Unconjugated

Properties

Form Liquid

Storage instructions Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes

section.

Storage buffer Phosphate buffered saline pH 7.4, contains stabilizer and ≤0.09% sodium azide.

Purity immunogen affinity purified

Purification notes This product was prepared by immunoaffinity chromatography using immunogen

peptide coupled to Sepharose 4B.

Conjugation notes -

Clonality Monoclonal

Isotype IgG



General notes

For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.

Our customer's feedback says the antibody worked great. If in case the antibody fails to give results then please contact our scientific support team for assistance.

Applications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.

Product Usage Information:

Application Dilutions

Western Blotting 3-5 ug/ml
Immunohistochemistry (Paraffin) 5-10 ug/ml
Immunohistochemistry (Frozen) 5-10 ug/ml
Immunofluorescence 5-10 ug/ml
Flow Cytometry 5-10 ug/ml


Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Background:

Fibromodulin is a protein that in humans is encoded by the FMOD gene.

Fibromodulin is a 42kDa protein of a family of small interstitial leucine-rich repeat proteoglycans (SLRPs). It can have up to four N-linked keratan sulfate chains attached to the core protein within the leucine-rich region. It shares significant sequence homology with biglycan and decorin.

References:



Chronic Lymphocytic Leukemia (CLL)

Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/10.

